Showing results (81-90 of 99) with videos related to
Sort By:
Pageof 10
Nature Communications|March 17, 2026
Durvalumab and cediranib with and without olaparib in recurrent ovarian cancer: a phase II proof-of-concept studyJunya Tabata, Tzu-Ting Huang, Elena Giudice, et al.Nature Communications|March 30, 2024
The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trialElena Giudice, Tzu-Ting Huang, Jayakumar R Nair, et al.Plos One|February 4, 2010
CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinasesYi-Hung Carol Tan, Soundararajan Krishnaswamy, Suvobroto Nandi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2017
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I StudyJung-Min Lee, Ashley Cimino-Mathews, Cody J Peer, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2020
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II StudyErika J Lampert, Alexandra Zimmer, Michelle Padget, et al.The Journal of Experimental Medicine|January 31, 2020
Sequential ubiquitination of NLRP3 by RNF125 and Cbl-b limits inflammasome activation and endotoxemiaJuan Tang, Sha Tu, Guoxin Lin, et al.Research Square|June 5, 2026
SYNTHESIS-Breast: A prospective early-phase trial of a genetic-interaction- focused computational algorithm in advanced metastatic breast cancerAanika B Warner, Britanny B Solarz, Miroslava Belyov, et al.Journal of Experimental & Clinical Cancer Research : CR|March 29, 2023
First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumorsChristopher B Cole, Maria Pia Morelli, Massimo Fantini, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2023
Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain MetastasesSarah Jenkins, Wei Zhang, Seth M Steinberg, et al.Biorxiv : the Preprint Server for Biology|January 8, 2024
NOS2 and COX2 Provide Key Spatial Targets that Determine Outcome in ER- Breast CancerLisa A Ridnour, William F Heinz, Robert Ys Cheng, et al.Pageof 10